BIGG Rec Logo
BIGG Rec Logo
Guideline

WHO consolidated guidelines on drug-resistant tuberculosis treatment

Year of Publication
2019
Issuing Institution
World Health Organization
Links
WHO IRIS

Recommendations

35 included recommendations

In multidrug-resistant TB or isoniazid-resistant, rifampicin-resistant TB patients on longer regimens, all three Group A agents and at least one Group B agent should be included to ensure that treatment starts with at least four TB agents likely to be effective, and that at least three agents are included for the rest of treatment after bedaquiline is stopped. If only one or two Group A agents are used, both Group B agents are to be included. If the regimen cannot be composed with agents from Groups A and B alone, Group C agents are added to complete it (Group A: fluoroquinolones (levofloxacin and moxifloxacin), bedaquiline and linezolid were considered highly effective and strongly recommended for inclusion in all regimens unless contraindicated.– Group B: clofazimine and cycloserine or terizidone were conditionally recommended as agents of second choice.– Group C: included all other medicines that can be used when a regimen cannot be composed with Group A and B agents. The medicines in Group C are ranked by the relative balance of benefit to harm usually expected of each)

Status
Maintained

Recommended in favor

Conditional

Powered byEpistemonikos Foundation